Skip to main content

Table 2 Characteristics of the 17 trials included in meta-analysis

From: Efficacy of hematopoietic stem cell mobilization regimens in patients with hematological malignancies: a systematic review and network meta-analysis of randomized controlled trials

Study Eligible patients Mobilization regimen No. of patients Age* Gender (male%)
Studies for MM      
Bouko et al. [26] Newly diagnosed MM, responders to 3–4 cycles of induction therapy G-CSF SD 23 NA NA
   Pegfilgrastim 12 mg 22 NA NA
   Pegfilgrastim 18 mg 22 NA NA
Czerw et al. [30] MM patients, age 18–65 years, CR or PR achieved after at least one line of therapy G-CSF SD 46 60 (37–65) 57%
   ID-AraC + G-CSF SD 44 56 (33–65) 61%
DiPersio et al. [33] Diagnosis of MM, age 18–78 years, in first or second CR or PR G-CSF SD 154 58.4 ± 8.6 68%
   G-CSF SD + Plerixafor SD 148 58.2 ± 8.4 70%
Nahi et al. [50] Diagnosis of MM, age ≥ 18 years, in CR or PR G-CSF SD 10 58 (42–69) 60%
   G-CSF SD + Plerixafor SD 10 59 (43–70) 40%
Ri et al. [55] Diagnosis of MM, age 20–75 years, in first or second CR or PR G-CSF SD 7 60 (49–67) 57%
   G-CSF SD + Plerixafor SD 7 60 (38–71) 57%
Silvennoinen et al. [58] Transplant-eligible MM patients aged ≤ 70 years G-CSF SD 35 63 (40–70) 54%
   CY + G-CSF RD 34 62 (48–69) 53%
Skopec et al. [59] Newly diagnosed MM treated with 3–6 cycles of Bor and Dex G-CSF SD 20 60 (35–69) 55%
   Pegfilgrastim 12 mg 19 64 (51–71) 47%
Valtola et al. [61] Transplant-eligible MM patients less than 70 years of age G-CSF SD 19 63 (52–70) 42%
   CY + G-CSF RD 17 58 (49–70) 59%
Studies for NHL      
DiPersio et al. [32] Diagnosis of NHL, age 18–78 years, in first or second CR or PR G-CSF SD 148 59 (22–75) 69%
   G-CSF SD + Plerixafor SD 150 56 (29–75) 67%
Kuruvilla et al. [43] Diagnosis of NHL, age 18–78 years, in first or second CR or PR G-CSF SD + Plerixafor SD 31 47.8 ± 13.6 55%
   G-CSF SD + Plerixafor FD 30 46.1 ± 13.4 60%
Liu et al. [44] NHL patients, age 18–65 years, achieving CR or PR after first- or second-line therapy G-CSF SD 50 50 (18–64) 50%
   G-CSF SD + YF-H-2015005 51 45 (18–65) 53%
Matsue et al. [48] Diagnosis of NHL, age 20–75 years, in first CR or PR G-CSF SD 16 63 (27–70) 75%
   G-CSF SD + Plerixafor SD 16 56 (39–73) 69%
Zhu et al. [66] Diagnosis of NHL, age 18–75 years, in first or second CR or PR G-CSF SD 50 43 (20–60) 52%
   G-CSF SD + Plerixafor SD 50 39 (18–66) 62%
  1. Bor, bortezomib; CR, complete remission; CY, cyclophosphamide; Dex, dexamethasone; FD, fixed dose; G-CSF, granulocyte colony-stimulating factor; HL, Hodgkin lymphoma; ID-AraC, intermediate-dose cytarabine; MM, multiple myeloma; NA, not available; NHL, non-Hodgkin lymphoma; PR, partial remission; RD, reduced dose; SD, standard dose; YF-H-2015005, a new CXCR4 antagonist
  2. *Age is presented as mean and range, or mean ± standard deviation
Back to article page

Stem Cell Research & Therapy

ISSN: 1757-6512